Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 11,331 matching trials from the live ClinicalTrials.gov search.

Filters: Cleveland, Ohio Clear all

Conditions: Osteoporosis
Interventions: Zoledronic Acid; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 65 Years to 89 Years · Female only
Enrollment: 7,700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 59
States / cities: Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 50 more

Conditions: Acute ST Segment Elevation Myocardial Infarction
Interventions: RPH-104 80 mg, Placebo; Biological · Drug
Lead sponsor: R-Pharm Overseas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Cleveland, Ohio • Charlottesville, Virginia • Richmond, Virginia

Conditions: Cystic Fibrosis, Pseudomonas Aeruginosa, Pseudomonas, Lung Infection, Lung Infection Pseudomonal
Interventions: AP-PA02, Placebo; Biological · Other
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 20
States / cities: Los Angeles, California • Tampa, Florida • Boise, Idaho + 16 more

Conditions: Hypertension, Hemorrhage
Interventions: clevidipine; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 14
States / cities: Washington D.C., District of Columbia • Honolulu, Hawaii • Baltimore, Maryland + 11 more

Conditions: Postoperative Atrial Fibrillation
Interventions: Amiodarone, DC-cardioversion, Rate Control; Drug · Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 523 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 17
States / cities: Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 13 more

Conditions: Stroke, Parkinson Disease, Multiple Sclerosis, Oropharyngeal Dysphagia, Alzheimer Disease, Dementia
Interventions: Dysphagia Detection System; Device
Lead sponsor: Société des Produits Nestlé (SPN); Industry
Eligibility: 18 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 12
States / cities: Downey, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more

Conditions: Colitis, Ulcerative
Interventions: GED-0301; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 20
States / cities: Newport Beach, California • San Diego, California • Gainesville, Florida + 16 more

Conditions: Chronic Migraine or Episodic Migraine
Interventions: Placebo, AMG 301; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 21
States / cities: Long Beach, California • Santa Monica, California • Boulder, Colorado + 18 more

Conditions: Leukemia
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, methotrexate, methylprednisolone, tacrolimus, laboratory biomarker analysis, pharmacological study, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation; Biological · Drug · Other + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 48
States / cities: Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 45 more

Conditions: B-cell Chronic Lymphocytic Leukemia
Interventions: Lenalidomide, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 56
States / cities: Phoenix, Arizona • Fountain Valley, California • San Diego, California + 48 more

Conditions: Human Papillomavirus
Interventions: Alinity m HR HPV; Diagnostic Test
Lead sponsor: Abbott Molecular; Industry
Eligibility: 25 Years and older · Female only
Enrollment: 14,935 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 63
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more

Conditions: Primary Hypertension
Interventions: LY2623091, Tadalafil, Spironolactone, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 33
States / cities: Glendale, Arizona • Concord, California • Encinitas, California + 28 more

Conditions: Pulmonary Hypertension
Interventions: Riociguat (Adempas, BAY63-2521), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 9
States / cities: La Jolla, California • Sacramento, California • Miami, Florida + 6 more

Conditions: Macular Telangiectasia Type 2
Interventions: NT-501 CNTF implant; Combination Product
Lead sponsor: Neurotech Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 4 more

Conditions: Mohs Micrographic Surgery
Interventions: 3D printed model, Verbal Counselling; Behavioral
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Dermatomyositis
Interventions: Anti-Beta Interferon (PF-06823859); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 21
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Beverly Hills, California + 8 more

Conditions: Migraine
Interventions: Rimegepant, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 636 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 27
States / cities: Phoenix, Arizona • Long Beach, California • Aurora, Colorado + 18 more

Conditions: Peripheral Arterial Disease
Interventions: Not listed
Lead sponsor: Baylor Research Institute; Other
Eligibility: Not listed
Enrollment: 14,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2033
U.S. locations: 24
States / cities: Little Rock, Arkansas • Denver, Colorado • Atlanta, Georgia + 17 more

Conditions: Acute Heart Failure
Interventions: Cinaciguat (BAY58-2667), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Ridgewood, New Jersey • Winston-Salem, North Carolina • Cleveland, Ohio + 2 more

Conditions: Endometrial Neoplasms
Interventions: olaparib, durvalumab, durvalumab placebo, olaparib placebo, Carboplatin, Paclitaxel; Drug · Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 150 Years · Female only
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 50
States / cities: Tucson, Arizona • Concord, California • La Jolla, California + 45 more

Conditions: Shoulder Pain
Interventions: Lidocaine, Triamcinolone + Lidocaine; Drug
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Chronic Pain, Back Pain, Pain
Interventions: Evoke Spinal Cord Stimulator (SCS) System; Device
Lead sponsor: Saluda Medical Americas, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 16
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Santa Rosa, California + 11 more

Conditions: Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Interventions: Not listed
Lead sponsor: LAPIX Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Baltimore, Maryland • Chevy Chase, Maryland • New York, New York + 1 more

Conditions: Acute Myeloid Leukemia
Interventions: Entospletinib, Daunorubicin, Cytarabine, Decitabine, Azacitidine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 14
States / cities: Los Angeles, California • Chicago, Illinois • Maywood, Illinois + 10 more

Search by objective public record fields.

HORIZON-PFT: Pivotal Fracture Trial

Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction

Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis

Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)

Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation

Videofluoroscopic Swallowing Study (VFSS)

An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis

Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention

Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia

A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy

Alinity m HR HPV Specimen Collection Study From Women Undergoing Routine Cervical Cancer Screening

A Study of LY2623091 in Participants With High Blood Pressure

A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.

Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2

3D Printed Models in Mohs Micrographic Surgery

An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

Multi-Center Registry for Peripheral Arterial Disease Interventions and Outcomes

BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

Subacromial Corticosteroid Injection for Hemiplegic Shoulder Pain

Safety and Efficacy Study of the Evoke™ SCS System With Feedback vs. Conventional Stimulation

An Observational Biomarker Study in Multiple Sclerosis (MS) Patients

Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)